Genetic polymorphisms and risk of breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 8, Issue 11, 1999, Pages 1023-1032

  Coughlin, Steven S ^a   Piper, Margaret ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 ISOENZYME; ESTROGEN; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE;

BREAST CARCINOMA; CANCER RISK; ESTROGEN METABOLISM; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; HORMONE TRANSPORT; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

BREAST NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENETIC MARKERS; HUMANS; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 0032725913     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., and King, M. C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science (Washington DC), 250: 1684-1689, 1990.
2. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., and Ding, W. A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA1. Science (Washington DC), 266: 66-71, 1994.
3. Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., and Averill, D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science (Washington DC), 265: 2088-2090, 1994.
4. Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., Sobol, H., Teare, M. D., Struewing, J., Arason, A., Scherneck, S., Peto, J., Rebbeck, T. R., Tonin, P., Neuhausen, S., Barkardottir, R., Eyfjord, J., Lynch, H., Ponder, B. A., Gayther, S. A., and Zelada-Hedman, M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet., 62: 676-689, 1998.
5. Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., and Tucker, M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med., 336: 1401-1408, 1997.
6. Newman, B., Mu, H., Butler, L. M., Millikan, R. C., Moorman, P. G., and King, M. C. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. J. Am. Med. Assoc., 279: 915-921, 1998.
7. Malone, K. E., Daling, J. R., Thompson, J. D., O'Brien, C. A., Francisco, L. V., and Ostrander, E. A. BRCA1 mutations and breast cancer in the general population. Analyses in women before age 35 years and in women before age 45 years with first-degree family history. J. Am. Med. Assoc., 279: 922-929, 1998.
8. Newman, B., Millikan, R. C., and King, M-C. Genetic epidemiology of breast and ovarian cancers. Epidemiol. Rev., 19: 69-79, 1997.
9. Coughlin, S. S., Khoury, M. J., and Sleinberg, K. K. BRCA1 and BRCA2 gene mutations and risk of breast cancer: public health perspectives. Am. J. Prev. Med., 16: 91-98, 1999.
10. Weston, A., and Godbold, J. H. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ. Health Perspect., 105 (Suppl. 4): 919-926, 1997.
11. Easton, D. F. Cancer risks in A-T heterozygotes. Int. J. Radiat. Biol., 66 (6 Suppl.): S177-S182, 1994.
12. Swift, M., Morrell, D., Massey, R. B., and Chase, C. L. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N. Engl. J. Med., 325: 1831-1836, 1991.
13. Vorechovsky, I., Luo, L., Lindblom, A., Negrini, M., Webster, A. D., Croce. C. M., and Hammarstrom, L. ATM mutations in cancer families. Cancer Res., 56: 4130-4133. 1996.
14. Athma, P., Rappaport, R., and Swift, M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet. Cytogenet., 92: 130-134, 1996.
15. FitzGerald, M. G., Bean, J. M., Hegde, S. R., Unsal, H., MacDonald, D. J., Harkin, D. P., Finkelstein, D. M., Isselbacher, K. J., and Haber, D. A. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat. Genet., 15: 307-311, 1997.
16. Bebb, G., Glickman, B., Gelmon, K., and Gatti, R. "AT risk" for breast cancer. Lancet, 349: 1784-1785, 1997.
17. Smith, G., Stanley, L. A., Sim, E., Strange, R. C., and Wolf, C. R. Metabolic polymorphisms and cancer susceptibility. Cancer Surv., 25: 27-65, 1995.
18. d'Errico, A., Taioli, E., Chen, X., and Vineis, P. Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers, 1: 149-173, 1996.
19. Ambrosone, C. B., Freudenheim, J. L., Marshall, J. R., Graham, S., Vena, J. E., Brasure, J. R., Michalek, A. M., Laughlin, R., Nemoto, T., and Shields, P. G. The association of polymorphic N-acetyltransferase (NAT2) with breast cancer risk. Ann. NY Acad. Sci., 768: 250-252, 1995.
20. Feigelson, H. S., Coetzee, G. A., Kolonel, L. N., Ross, R. K., and Henderson, B. E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res., 57: 1063-1065, 1997.
21. Strong, L. C., and Amos, C. I. Inherited susceptibility. In: D. Schottenfeld and J. F. Fraumeni (eds.), Cancer Epidemiology and Prevention, Ed. 2, pp. 559-83. New York: Oxford University Press, 1996.
22. Murray, G. I., Foster, C. O., Barnes, T. S., Weaver, R. J., Ewen, S. W., Melvin, W. T., and Burke, M. D. Expression of cytochrome P4501a in breast cancer. Br. J. Cancer, 63: 1021-1023, 1991.
23. Rebbeck, T. R., Rosvold, E. A., Duggan, D. J., Zhang, J., and Buetow, K. H. Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer. Cancer Epidemiol. Biomark. Prev., 3: 511-514, 1994.
24. Martucci, C. P., and Fishman, J. P450 enzymes of estrogen metabolism. Pharmacol. Ther., 57: 237-257, 1993.
25. Taioli, E., Trachman, J., Chen, X., Toniolo, P., and Garte, S. J. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res., 55: 3757-3758, 1995.
26. Ishibe, N., Hankinson, S. E., Colditz, G. A., Spiegelman, D., Willett, W. C., Speizer, F. E., Kelsey, K. T., and Hunter, D. J. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res., 58: 667-671, 1998.
27. Sivaraman, L., Leatham, M. P., Yee, J., Wilkens, L. R., Lau, A. F., and Le Marchand, L. CYP1A1 genetic polymorphism and in situ colorectal cancer. Cancer Res., 54: 3692-3695, 1994.
28. Ambrosone, C. B., Freudenheim, J. L., Graham, S., Marshall, J. R., Vena, J. E., Brasure, J. R., Laughlin, R., Nemoto, T., Michalek, A. M., Harrington, A., Ford, T. D., and Shields, P. G. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res., 55: 3483-3485, 1995.
29. Kato, S., Onda, M., Matsukura, N., Tokunaga, A., Matsuda, N., Higuchi, K., Furukawa, K., Yamashita, K., and Shields, P. G. Cytochrome P450 1A1 (CYP1A1) and glutathione-S-transferase M1 (CSTM1) genetic polymorphisms for gastric and breast cancer risk. Proc. Annu. Meet. Am. Assoc. Cancer Res., 37: A1768, 1996.
30. Smith, C. A. D., Moss, J. E., Gough, A. C., Spurr, N. K., and Wolf, C. R. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ. Health Perspect., 98: 107-112, 1992.
31. Wolf, C. R., Smith, C. A. D., Gough, A. C., Moss, J. E., Vallis, K. A., Howard, G., Carey, F. J., Mills, K., McNee, W., Carmichael, J., and Spurr, N. K. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis (Lond.), 13: 1035-1038, 1992.
32. Buchert, E. T., Woosley, R. L., Swain, S. M., Oliver, S. J., Coughlin, S. S., Pickle, L., Trock, B., and Riegel, A. T. Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility. Pharmacogenetics, 3: 322-327, 1993.
33. Ladona, M. G., Abildua, R. E., Ladero, J. M., Roman, J. M., Plaza, M. A., Agundez, J. A. G., Munoz, J. J., and Benitez, J. CYP2D6 genotypes in Spanish women with breast cancer. Cancer Lett., 99: 23-28, 1996.
34. Ladero, J. M., Benitez, J., Jara, C., Llerena, A., Valdivielso, M. J., Munoz, J. J., and Vargas, E. Polymorphic oxidation of debrisoquine in women with breast cancer. Oncology, 48: 107-110, 1991.
35. Pontin, J. E., Hamed, H., Fentiman, I. S., and Idle, J. R. Cytochrome P450db1 phenotypes in malignant and benign breast disease. Eur. J. Cancer, 26: 790-792, 1990.
36. Huober, J., Bertram, B., Petru, E., Kaufmann, M., and Schmahl, D. Metabolism of debrisoquine and susceptibility to breast cancer. Br. Cancer Res. Treat., 18: 43-48, 1991.
37. Feigelson, H. S., Shames, L. S., Pike, M. C., Coetzee, G. A., Stanczyk, F. Z., and Henderson, B. E. Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentration. Cancer Res., 58: 585-587, 1998.
38. Feigelson, H. S., Ross, R. K., Yu, M. C., Coetzee, G. A., Reichardt, J. K., and Henderson, B. E. Genetic susceptibility to cancer from exogenous and endogenous exposures. J. Cell Biochem., 25S: 15-22, 1996.
39. Helzlsouer, K. J., Huang, H. Y., Strickland, P. T., Huffman, S., Alberg, A. J., Comstock, G. W., and Bell, D. A. Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol. Biomark. Prev., 7: 945-949, 1998.
40. Haiman, C. A., Hankinson, S. E., Spiegelman, D., Colditz, G. A., Willett, W. C., Speizer, F. E., Kelsey, K. T., and Hunter, D. J. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res., 59: 1015-1020, 1999.
41. Weston, A., Pan, C. F., Bleiweiss, I. J., Ksieski, H. B., Roy, N., Maloney, N., and Wolff, M. S. CYP17 genotype and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 7: 941-944, 1998.
42. Dunning, A. M., Healey, C. S., Pharoah, P. D., Foster, N. A., Lipscombe, J. M., Redman, K. L., Easton, D. F., Day, N. E., and Ponder, B. A. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br. J. Cancer, 77: 2045-2047, 1998.
43. Ambrosone, C. B., Freudenheim, J. L., Graham, S., Marshall, J. R., Vena, J. E., Brasure, J. R., Michalek, A. M., Laughlin, R., Nemoto, T., Gillenwater, K. A., Harrington, A. M., and Shields, P. G. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms and breast cancer risk. J. Am. Med. Assoc., 276: 1494-1501, 1996.
44. Bulovskaya, L. N., Krupkin, R. G., Bochina, T. A., Shipkova, A. A., and Pavlova, M. V. Acetylator phenotype in patients with breast cancer. Oncology, 35: 185-188, 1978.
45. Sardas, S., Cod, I., and Sardas, O. S. Polymorphic N-acetylation capacity in breast cancer patients. Int. J. Cancer, 46: 1138-1139, 1990.
46. Philip, P. A., Rogers, H. J., Millis, R. R., Rubens, R. D., and Cartwright, R. A. Acetylator status and its relationship to breast cancer and other diseases of the breast. Eur. J. Cancer Clin. Oncol., 23: 1701-1706, 1987.
47. Agundez, J. A., Ladero, J. M., Olivera, M., Abildua, R., Roman, J. M., and Benitez, J. Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. Oncology, 52: 7-11, 1995.
48. Millikan, R. C., Pittman, G. S., Newman, B., Tse, C. K. J., Selmin, O., Rockhill, B., Savitz, D., Moorman, P. G., and Bell, D. A. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 7: 371-378, 1998.
49. Hunter, D. J., Hankinson, S. E., Hough, H., Gertig, D. M., Garcia-Closas, M., Spiegelman, D., Manson, J. A. E., Colditz, G. A., Wiliett, W. C., Speizer, F. E., and Kelsey, K. A prospective study of NAT2 acetylation genotype, cigarette smoking and risk of breast cancer. Carcinogenesis (Lond.), 18: 2127-2132, 1997.
50. Rebbeck, T. R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomark. Prev., 6: 733-743, 1997.
51. Helzlsouer, K. J., Selmin, O., Huang, H-Y., Strickland, P. T., Huffman, S., Alberg, A. J., Watson, M., Comstock, G. W., and Bell, D. Association between glulathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J. Natl. Cancer Inst., 90: 512-518, 1998.
52. Zhong, S., Wyllie, A. H., Barnes, D., Wolf, C. R., and Spurr, N. K. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis (Lond.), 14: 1821-1824, 1993.
53. Kelsey, K. T., Hankinson, S. E., and Colditz, G. A. Glutathione S-transferase class μ deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiol. Biomark. Prev., 6: 511-515, 1997.
54. Rebbeck, T. R., Walker, A. H., Phelan, C. M., Godwin, A. K., Buetow, K. H., Garber, J. E., Narod, S. A., and Weber, B. L. Defining etiologic heterogeneity in breast cancer using genetic biomarkers. In: Etiology of Breast and Gynecological Cancers, pp. 53-61. New York: Wiley-Liss, Inc., 1997.
55. Roodi, N., Bailey, L. R., Kao, W. Y., Verrier, C. S., Yee, C. J., Dupont, W. D., and Parl, F. F. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J. Natl. Cancer Inst., 87: 446-451, 1995.
56. Potter, J. D., Cerhan, J. R., Sellers, T. A., McGovern, P. G., Drinkard, C., Kushi, L. R., and Folsom, A. R. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol. Biomark. Prev., 4: 31926, 1995.
57. Rayter, Z. Steroid receptors in breast cancer. Br. J. Surg., 78: 528-535, 1991.
58. Donegan, W. L. Prognostic factors-stage and receptor status in breast cancer. Cancer (Phila.), 70: 1755-1764, 1992.
59. Yoo, K. Y., Tajima, K., Miura, S., Takeuchi, T., Hirose, K., Risch, H., and Dubrow, R. Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis. Am. J. Epidemiol., 146: 307-314, 1997.
60. Elwood, J. M., and Godolphin, W. Oestrogen receptors in breast tumors: associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br. J. Cancer, 42: 635-644, 1980.
61. Lesser, M. L., Rosen, P. P., Senie, R. T., Duthie, K., Menendez-Botet, C., and Schwartz, M. K. Estrogen and progesterone receptors in breast carcinoma: correlations with epidemiology and pathology. Cancer (Phila.), 48: 299-309, 1981.
62. Hildreth, N. G., Kelsey, J. L., Eisenfeld, A. J., LiVolsi, V. A., Holford, T. R., and Fischer, D. B. Differences in breast cancer risk factors according to the estrogen receptor level of the tumor. J. Natl. Cancer Inst., 70: 1027-1031, 1983.
63. Hulka, B. S., Chambless, L. E., Wilkinson, W. E., Deubner, D. C., McCarty, K. S., Sr., McCarty, K. S., Jr. Hormonal and personal effects on estrogen receptors in breast cancer. Am. J. Epidemiol., 119: 692-704, 1984.
64. McTiernan, A., Thomas, D. B., Johnson, L. K., and Roseman, D. Risk factors for estrogen receptor-rich and estrogen receptor-poor breast cancers. J. Natl. Cancer Inst., 77: 849-854, 1986.
65. Ballard-Barbash, R., Griffin, M. R., Fisher, L. D., Covalciuc, M. A., and Jiang, N. S. Estrogen receptors in breast cancer: association with epidemiologic risk factors. Am. J. Epidemiol., 124: 77-84, 1986.
66. Hislop, T. G., Coldman, A. J., Elwood, J. M., Skippen, D. H., and Kan, L. Relationship between risk factors for breast cancer and hormonal status. Int. J. Epidemiol., 15: 469-476, 1986.
67. Stanford, J. L., Szklo, M., Boring, C. C., Brinton, L. A., Diamond, E. A., Greenberg, R. S., and Hoover, R. N. A case-control study of breast cancer stratified by estrogen receptor status. Am. J. Epidemiol., 125: 184-194, 1987.
68. Kreiger, N., King, W. D., Rosenberg, L., Clarke, E. A., Palmer, J. R., and Shapiro, S. Steroid receptor status and the epidemiology of breast cancer. Ann. Epidemiol., 1: 513-523, 1991.
69. Nasca, P. C., Liu, S., Baptiste, M. S., Kwon, C. S., Jacobson, H., and Metzger, B. B. Alcohol consumption and breast cancer: estrogen receptor status and histology. Am. J. Epidemiol., 140: 980-988, 1994.
70. Sellers, T. A. Genetic factors in the pathogenesis of breast cancer: their role and relative importance. J. Nutr., 127: 929, 1997.
71. Southey, M. C., Batten, L. E., McCredie, M. R. E., Giles, G. G., Dite, G., Hopper, J. L., and Venter, D. J. Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty. J. Natl. Cancer. Inst., 90: 532-536, 1998.
72. Andersen, T. I., Heimdal, K. R., Skrede, M., Tveit, K., Berg, K., and Borresen, A-L. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum. Genet., 94: 665-670, 1994.
73. Andersen, T. I., Wooster, R., Laake, K., Collins. N., Warren, W., Skrede, M., Elles, R., Tveit, K. M., Johnston, S. R., Dowsett, M., Olsen, A. O., Moller, P., Stratton, M. R., and Borresen-Dale, A. L. Screening for ESR mutations in breast and ovarian cancer patients. Hum. Mutat., 9: 531-536, 1997.
74. Zelada-Hedman, M., Borresen-Dale, A. L., and Lindblom, A. Screening of 229 family cancer patients for a germline estrogen receptor gene (ESR) base mutation. Hum. Mutat., 9: 289, 1997.
75. Nebert, D. W. Elevated estrogen 16 α-hydroxylase activity: is this a genotoxic or nongenotoxic biomarker in human breast cancer risk? J. Natl. Cancer Inst., 85: 1888-1891, 1993.
76. Bradlow, H. L., Hershcopf, R., Martucci, C., and Fishman, J. 16α-Hydroxylation of estradiol: a possible risk marker for breast cancer. Ann. NY Acad. Sci., 464: 138-151, 1986.
77. Liehr, J. G. Genotoxic effects of estrogens. Mutat. Res., 238: 269-276, 1990.
78. Fishman, J., Osborne, M. P., and Telang, N. T. The role of estrogen in mammary carcinogenesis. Ann. NY Acad. Sci., 768: 91-100, 1995.
79. Liehr, J. G. Genotoxic effects of estrogens. Mutat. Res., 238: 269-276, 1990.
80. Service, R. F. New role for estrogen in cancer? Science (Washington DC), 279: 1631-1633, 1998.
81. Yager, J. D., and Liehr, J. G. Molecular mechanisms of estrogen carcino-genesis. Annu. Rev. Pharmacol. Toxicol., 36: 203-232, 1996.
82. Ashburn, S. P., Han, X., and Liehr, J. G. Microsomal hydroxylation of 2- and 4-fluoroestradiol to catechol metabolites and their conversion to methyl ethers: catechol estrogens as possible mediators of hormonal carcinogenesis. Mol. Pharmacol., 43: 534-541, 1993.
83. Lavigne, J. A., Helzlsouer, K. J., Huang, H-Y., Strickland, P. T., Bell, D. A., Selmin, O., Watson, M. A., Huffman, S., Comstock, G. W., and Yager, J. D. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res., 57: 5493-5497, 1997.
84. Lemon, H. M., Heidel, J. W., and Rodriguez-Sierra, J. F. Increased catechol estrogen metabolism as a risk factor for nonfamilial breast cancer. Cancer (Phila.), 69: 457-465, 1992.
85. Weisz, J., Bui, Q. D., Roy, D., and Liehr, J. G. Elevated 4-hydroxylation of estradiol by hamster kidney microsomes: a potential pathway of metabolic activation of estrogens. Endocrinology, 131: 655-661, 1992.
86. Liehr, J. G., and Ricci, M. J. 4-Hydroxylation of estrogens as a marker of human mammary tumors. Proc. Natl. Acad. Sci. USA, 93: 3294-3296, 1996.
87. Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y. M., Szumlanski, C. L., and Weinshilboum, R. M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6: 243-250, 1996.
88. Zhu, B. T., and Liehr, J. G. Quercetin increases the severity of estradiol-induced tumorigenesis in hamster kidney. Toxicol. Appl. Pharmacol., 125: 149-158, 1994.
89. Zhu, B. T., and Liehr, J. G. Inhibition of catechol-O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by quercetin. Possible role in estradiol-induced tumorigenesis. J. Biol. Chem., 271: 357-363, 1996.
90. Scanlon, P. D., Raymond, F. A., and Weinshilboum, R. M. Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science (Washington DC), 203: 63-65, 1979.
91. Thompson, P. A., Shields, P. G., Fruedenheim, J. L., Stone, A., Vena, J. E., Marshall, J. R., Graham, S., Laughlin, R., Nemoto, T., Kadlubar, F. F., and Ambrosone, C. B. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res., 58: 2107-2110, 1998.
92. Berta, L., Frairia, R., Fortunati, N., Fazzari, A., and Gaidano, G. Smoking effects on the hormonal balance of fertile women. Horm. Res., 37: 45-48, 1992.
93. Millikan, R. C., Pittman, G. S., Tse, C. K. J., Duell. E., Newman, B., Savitz, D., Moorman, P. G., Boissy, R. J., and Bell, D. A. Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis (Lond.), 19: 1943-1947, 1998.
94. Newman, B., Moorman, P. G., Millikan, R., Qaqish, B. F., Geradts, J., Aldrich, T. E., and Liu, E. T. The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Br. Cancer Res. Treat., 35: 51-60, 1995.
95. Kaiser, J. Environment institute lays plans for gene hunt. Science (Washington DC), 278: 569-570, 1997.